HEOR Senior Director
Celldex Therapeutics
HEOR Senior Director
Celldex Therapeutics
Develops antibody-based therapies targeting inflammatory diseases
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. We have built a culture where innovative and talented people thrive—focusing a significant effort on attracting and retaining passionate and motivated employees who want to play a role in helping people with serious health conditions and who see this effort as personally rewarding. In our highly entrepreneurial environment, employees are empowered and the opportunity for professional development occurs every day.
The US HEOR lead is a critical member of the HEOR team that serves as the US healthcare decision maker voice in the Medical Affairs and Evidence Generation Department. The Senior Director, US HEOR works collaboratively with cross-functional partners including medical affairs, market access, commercial, regulatory and others to align on the value of barzolvolimab and other pipeline products and their place in therapy. The Senior Director serves as a subject matter expert in US payer landscape, PIE, US models and dossiers. The US HEOR lead will work with in-house teams and partner closely with Field Medical, Market Access, and future field-based HEOR capabilities to translate evidence into actionable insights for healthcare decision makers. This role will incorporate field-generated payer, provider, and health system insights into evidence generation and value communication strategies. This position will report to the Executive Director of HEOR.
Develops antibody-based therapies targeting inflammatory diseases
Celldex Therapeutics develops antibody-based therapies for inflammatory, allergic, and autoimmune diseases, focusing on mast cell biology. Its lead program barzolvolimab is a humanized monoclonal antibody that inhibits KIT, reducing mast cell activity and inflammation; its pipeline includes other antibodies designed to engage the immune system or modulate disease pathways. The company leverages partnerships and licensing in addition to developing its own therapies to create a breadth of programs in its target areas. Its goal is to deliver therapies that lessen inflammation and autoimmune activity by targeting mast cells and related signaling pathways.
Explore more opportunities at Celldex Therapeutics